Eli Lilly and Company

Report azionario NYSE:LLY

Capitalizzazione di mercato: US$882.7b

Eli Lilly Crescita futura

Criteri Future verificati 3/6

Eli Lilly prevede che gli utili e i ricavi cresceranno rispettivamente di 16.7% e 12.4% all'anno. Si prevede che l'EPS crescerà di 16.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 49.9% in 3 anni.

Informazioni chiave

16.7%

Tasso di crescita degli utili

16.86%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili14.4%
Tasso di crescita dei ricavi12.4%
Rendimento futuro del capitale proprio49.90%
Copertura analitica

Good

Ultimo aggiornamento13 May 2026

Aggiornamenti recenti sulla crescita futura

Articolo di analisi • Feb 07

Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think

Investors in Eli Lilly and Company ( NYSE:LLY ) had a good week, as its shares rose 2.0% to close at US$1,058 following...

Recent updates

Seeking Alpha • May 10

Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions

Summary Eli Lilly remains a 'strong buy' as I see robust revenue growth across obesity, diabetes, immunology, and oncology franchises. LLY’s MOUNJARO and ZEPBOUND delivered Q1 2026 revenues of $8.66B [+125%] and $4.16B [+80%] respectively, driving a 56% YoY total revenue increase. Pipeline momentum is strong: FOUNDAYO launched, Retatrutide and Eloralintide advanced, and EBGLYSS/JAYPIRCA show double-digit growth with label expansion catalysts ahead. I maintain my 'strong buy' rating, reinforced by a $2B increase of full-year 2026 revenue guidance and multiple near-term clinical/regulatory milestones expected. Read the full article on Seeking Alpha
Aggiornamento della narrazione • May 07

LLY: Obesity Pricing Pressure And Safety Headlines Will Shape Future Franchise Economics

Analysts have raised Eli Lilly's implied fair value from $883.99 to $899.73 after several firms increased their price targets by $1 to $50, citing confidence in the obesity and diabetes pipeline, Foundayo's regulatory progress, and clarifications around recent safety concerns. Analyst Commentary Recent research on Eli Lilly reflects a mix of enthusiasm around obesity and diabetes assets and a clearer, more cautious minority that is focused on how much optimism is already reflected in the stock.
Aggiornamento della narrazione • Apr 20

LLY: Obesity And Diabetes Platform Will Support Premium Positioning Beyond 2030

Analysts have slightly raised their average price targets on Eli Lilly in recent weeks, citing supportive trial updates in obesity and diabetes, favorable comparisons to competing GLP-1 therapies, and regulatory progress that they say supports high but unchanged fair value estimates of around $1,500. Analyst Commentary Recent Street research around Eli Lilly has been active, with a cluster of price target moves, rating changes, and product specific notes that give you a clearer sense of how professionals are framing the risk and reward.
Aggiornamento della narrazione • Apr 06

LLY: Oral GLP-1 Launch And Capacity Expansion Will Drive Future Obesity Upside

Analysts have nudged Eli Lilly's price target slightly higher by $1, reflecting updated views on obesity and diabetes franchises following recent Foundayo approval commentary and comparative GLP-1 data. Analyst Commentary Recent research on Eli Lilly clusters around obesity and diabetes, pricing dynamics in GLP-1 therapies, and the implications of new product approvals and trial readouts for long term growth and valuation.
Nuova narrazione • Mar 25

Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth

Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet. WHERE THE STOCK SITS TODAY The current price is around $907 (25/03/2026).
Aggiornamento della narrazione • Mar 23

LLY: Obesity And Diabetes Franchise Strength Will Support Premium Positioning

Analysts have raised their price target for Eli Lilly to $1,500, citing updated models that reflect slightly stronger assumed revenue growth, a marginally higher profit margin profile, and continued confidence in the obesity and diabetes franchises following recent trial data and supportive sell side research. Analyst Commentary Recent research highlights a split view on Eli Lilly, with some bullish analysts leaning into the obesity and diabetes opportunity set, while at least one more cautious voice questions how much growth is already reflected in the share price.
Aggiornamento della narrazione • Mar 09

LLY: Obesity Drug Leadership And Pipeline Catalysts Will Sustain Premium Positioning

The updated analyst price target for Eli Lilly has increased to $1,490.52 from $1,429.89. Analysts highlight the obesity and GLP-1 franchise, premium valuations tied to weight loss leadership, and potential upside from pipeline and acquisition catalysts as key factors supporting this change.
Aggiornamento della narrazione • Feb 23

LLY: GLP-1 Obesity Leadership Will Drive Future Cardiometabolic And M&A Upside

Eli Lilly's analyst price targets have shifted higher, with our fair value estimate moving from $1,093.22 to $1,211.21, as analysts point to sustained GLP-1 obesity leadership, premium valuation support, and an expanding cardiometabolic pipeline as key drivers of their updated views. Analyst Commentary Recent Street research on Eli Lilly clusters around a few clear themes, with bullish analysts focusing on obesity leadership, cardiometabolic breadth, and M&A, while more cautious voices watch valuation and execution risk around the pipeline.
Aggiornamento della narrazione • Feb 08

LLY: Government Pricing Deals Will Compress Obesity Franchise Economics Going Forward

Analysts have raised their fair value estimate for Eli Lilly from US$770 to about US$884 per share, reflecting updated assumptions on long term obesity opportunities, recent price target increases across several firms, and steady expectations around margins and future P/E multiples. Analyst Commentary The latest batch of research on Eli Lilly revolves around its weight loss and cardiometabolic franchises, expectations for new product launches, and the implications of recent policy developments on pricing and access.
Articolo di analisi • Feb 07

Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think

Investors in Eli Lilly and Company ( NYSE:LLY ) had a good week, as its shares rose 2.0% to close at US$1,058 following...
Aggiornamento della narrazione • Jan 25

LLY: Government GLP 1 Pricing Deals Will Pressure Obesity Margins

Analysts have nudged their price targets on Eli Lilly slightly higher, citing continued confidence in the obesity and GLP 1 franchise, supportive government pricing agreements, and potential upside from acquisitions and pipeline catalysts, even as some firms fine tune their models and individual targets by low single digit amounts such as Guggenheim's recent US$2 trim. Analyst Commentary Recent research on Eli Lilly has been dominated by optimism around obesity treatments and government pricing agreements, but there is also a pocket of caution that is worth paying attention to if you are thinking about valuation, execution and long term growth risk.
Aggiornamento della narrazione • Jan 11

LLY: GLP-1 Pricing Deals Will Pressure Obesity Margins Going Forward

Analysts lifted their fair value estimate for Eli Lilly from US$650 to US$770, citing higher assumed profit margins, a slightly higher discount rate, updated expectations for revenue growth and future P/E, and continued Street support related to the obesity franchise, GLP-1 pricing agreements, and pipeline catalysts. Analyst Commentary Recent Street research around Eli Lilly has been dominated by views on obesity drugs, pricing agreements with the U.S. government, and the company’s expanding pipeline.
Aggiornamento della narrazione • Dec 27

LLY: GLP-1 Pricing Deals And Policy Will Shape Future Obesity Leadership And Risks

Analysts have lifted their fair value estimate for Eli Lilly to approximately $1,093 from about $1,024, reflecting expectations for stronger long term GLP 1 driven revenue growth, expanding profit margins and sustained leadership in the obesity market, supported by recent U.S. reimbursement and pricing deals. Analyst Commentary Street research remains broadly constructive on Eli Lilly, with a series of upward price target revisions and fresh coverage initiations underscoring confidence in the durability of its GLP 1 franchise and broader innovation pipeline.
Aggiornamento della narrazione • Dec 13

LLY: Government Access Deals Will Drive Durable Obesity And Diabetes Leadership

Analysts have raised their fair value estimate for Eli Lilly shares from approximately $1,170 to about $1,430 per share, reflecting higher expected profitability and sustained leadership in the GLP 1 obesity and diabetes market, supported by recent U.S. government access deals and upcoming launches such as orforglipron. Analyst Commentary Bullish analysts continue to frame Eli Lilly as a core beneficiary of the expanding obesity and diabetes treatment market, with valuation upside tied to both higher GLP 1 penetration and a broadening metabolic pipeline.
Aggiornamento della narrazione • Nov 29

LLY: Upcoming Price Discounts And Policy Decisions Will Influence Drug Market Leadership And Risks

Eli Lilly's analyst price target has increased by approximately $21 to $1,024. Analysts cite earnings upside, expanding obesity drug opportunities, and recently announced government reimbursement agreements as key drivers of improved growth and profitability expectations.
Articolo di analisi • Nov 25

Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%

Despite an already strong run, Eli Lilly and Company ( NYSE:LLY ) shares have been powering on, with a gain of 30% in...
Aggiornamento della narrazione • Nov 21

GLP-1 drugs part of medicare

Short update, this is more bullish news about the demand for GLP-1 drugs in general spurring growth in this type of weight loss drug. Also, earnings report have showed that increase in earnings have been driven by increase in volume of GLP-1 drugs.
Aggiornamento della narrazione • Nov 15

LLY: Upcoming Drug Price Reductions and Policy Debates Will Shape Future Opportunities and Risks

The analyst price target for Eli Lilly has increased by over $80 to approximately $1,003 per share. Analysts point to accelerating revenue growth, higher profit margins, and ongoing strength in the company's obesity drug franchise as drivers of greater long-term value.
Articolo di analisi • Nov 07

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Eli Lilly and Company's ( NYSE:LLY ) stock was strong after they recently reported robust earnings. However, we think...
Aggiornamento della narrazione • Nov 01

LLY: Upcoming Drug Launches And Global Expansion Will Shape Future Outlook

Eli Lilly’s fair value estimate has increased from $891.62 to $919.33. This reflects analysts' upward price target revisions following stronger than expected quarterly results and an improved earnings outlook.
Nuova narrazione • Sep 19

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.

Previsioni di crescita degli utili e dei ricavi

NYSE:LLY - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2028110,48444,96634,94245,55623
12/31/202798,04737,83528,66539,75028
12/31/202685,40130,98720,78932,20824
3/31/202672,24925,27710,58620,480N/A
12/31/202565,17920,6406,18216,813N/A
9/30/202559,42118,4127,03716,063N/A
6/30/202553,25913,80055010,939N/A
3/31/202549,00411,106-6699,318N/A
12/31/202445,04310,5901,0158,818N/A
9/30/202440,8638,370-2,2756,032N/A
6/30/202438,9237,342-2,0244,510N/A
3/31/202435,9326,138-2,2923,676N/A
12/31/202334,1245,240-1,5484,240N/A
9/30/202332,0734,9881,4696,215N/A
6/30/202329,5166,4983,3076,242N/A
3/31/202327,6915,6873,8816,793N/A
12/31/202228,5416,2454,6967,586N/A
9/30/202229,2406,0335,4048,080N/A
6/30/202229,0715,6924,9507,494N/A
3/31/202229,3236,1295,8248,086N/A
12/31/202128,3185,5825,6047,366N/A
9/30/202127,7595,9724,6216,919N/A
6/30/202126,7266,0714,8377,095N/A
3/31/202125,4866,0935,5657,815N/A
12/31/202024,5406,1944,4716,500N/A
9/30/202023,2145,5735,1126,648N/A
6/30/202022,9505,6184,8906,352N/A
3/31/202023,0875,5333,6844,908N/A
12/31/201922,3204,638N/A4,837N/A
9/30/201921,8434,264N/A4,322N/A
6/30/201921,6734,103N/A4,933N/A
3/31/201921,6222,545N/A5,399N/A
12/31/201821,4933,151N/A5,525N/A
9/30/201822,016372N/A5,819N/A
6/30/201822,368-166N/A5,579N/A
3/31/201822,6071,074N/A5,712N/A
12/31/201719,974-86N/A5,616N/A
9/30/201722,4712,225N/A5,879N/A
6/30/201722,0052,447N/A5,659N/A
3/31/201721,5852,187N/A5,410N/A
12/31/201621,2222,738N/A4,851N/A
9/30/201620,8372,444N/A3,841N/A
6/30/201620,6052,466N/A3,284N/A
3/31/201620,1792,319N/A2,830N/A
12/31/201519,9592,408N/A2,965N/A
9/30/201519,7042,359N/A3,318N/A
6/30/201519,6202,059N/A3,905N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di LLY ( 16.7% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di LLY ( 16.7% all'anno) cresceranno più lentamente rispetto al mercato US ( 16.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di LLY cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di LLY ( 12.4% all'anno) crescerà più rapidamente del mercato US ( 11.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di LLY ( 12.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di LLY sarà molto alto tra 3 anni ( 49.9 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/13 12:33
Prezzo dell'azione a fine giornata2026/05/13 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Eli Lilly and Company è coperta da 53 analisti. 28 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David ToungArgus Research Company
Emily FieldBarclays
Kerry HolfordBerenberg